Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Equity Income (2023 - 2025)

Historic Equity Income for Perspective Therapeutics (CATX) over the last 3 years, with Q1 2025 value amounting to -$1000.0.

  • Perspective Therapeutics' Equity Income rose 5000.0% to -$1000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was -$3000.0, marking a year-over-year increase of 7272.73%. This contributed to the annual value of -$8000.0 for FY2024, which is 5294.12% up from last year.
  • According to the latest figures from Q1 2025, Perspective Therapeutics' Equity Income is -$1000.0, which was up 5000.0% from -$2000.0 recorded in Q4 2024.
  • Over the past 5 years, Perspective Therapeutics' Equity Income peaked at -$1000.0 during Q1 2025, and registered a low of -$12000.0 during Q3 2023.
  • For the 3-year period, Perspective Therapeutics' Equity Income averaged around -$4333.3, with its median value being -$3000.0 (2024).
  • As far as peak fluctuations go, Perspective Therapeutics' Equity Income surged by 6000.0% in 2024, and later skyrocketed by 5000.0% in 2025.
  • Perspective Therapeutics' Equity Income (Quarter) stood at -$5000.0 in 2023, then skyrocketed by 60.0% to -$2000.0 in 2024, then skyrocketed by 50.0% to -$1000.0 in 2025.
  • Its Equity Income stands at -$1000.0 for Q1 2025, versus -$2000.0 for Q4 2024 and -$4000.0 for Q2 2024.